There exists a need for effective salvage regimens for multiple myeloma patients being considered for reducedintensity allogeneic hematopoietic SCT (RI-alloHSCT). We developed EPOCH-F, a regimen consisting of infusional etoposide, VCR and adriamycin with prednisone, CY and fludarabine to achieve both tumor control and host lymphocyte depletion to facilitate engraftment before RIalloHSCT. In all, 22 multiple myeloma patients were treated with EPOCH-F before RI-alloHSCT. The median age was 53 years (range 36-65), and the median number of previous therapies was 2 (range 1-8). Patients received a median of three cycles (range 1-5) of EPOCH-F. Toxicities were primarily hematologic and manageable. Median lymphocyte counts decreased from 1423/lL (range 335-2788) to 519/lL (range 102-1420; P ¼ 0.0002). The overall response (XPR) to EPOCH-F was 22 with 13% achieving a CR/near-complete response (nCR); only 1 patient progressed while on therapy. A total of 20 patients underwent RI-alloHSCT. Median day þ 100 donor chimerism was 100% (range 60-100). In all, 70% of patients achieved very good partial response or better response after transplant; 40% of patients achieved CR/nCR. TRM at 100 days and 5 years was 5 and 30%, respectively. Median OS after RI-alloHSCT was 46.1 months. EPOCH-F provides disease control and host lymphocyte depletion with consistent full donor engraftment in multiple myeloma patients undergoing RI-alloHSCT.
Introduction
Despite the significant advancements in treating patients with multiple myeloma, it remains essentially an incurable disease. 1 Although high-dose therapy with autologous hematopoietic SCT (HSCT) has been shown to improve survival, the overwhelming majority of patients experience recurrence or progression of their disease. 2, 3 There have been significant improvements in outcomes with the introduction of novel agents, such as bortezomib and lenalidomide, with their inclusion in pre-transplant induction, maintenance and salvage therapy; however, disease recurrence and progression remain significant clinical problems. [3] [4] [5] A potential therapeutic option for patients with relapsed and advanced multiple myeloma is allogeneic HSCT (alloHSCT), which can potentially result in a clinical benefit mediated by a graft-versus-myeloma effect. [6] [7] [8] [9] The use of this procedure has been limited because of the variable potency of the graft-versus-myeloma effect, the inherent risk of GVHD and a relatively high incidence of TRM when compared with its use in other hematologic malignancies. 7, 10 However, the introduction of reducedintensity (RI) and non-myeloablative conditioning regimens, which have been associated with a significant reduction in TRM, has led to a renewed interest in the clinical investigation of alloHSCT in patients with multiple myeloma.
11 -13 Clinical trials with RI and non-myeloablative AlloHSCT have suggested that myeloma patients with disease who remain sensitive to chemotherapy and who achieve full donor chimerism after transplant may derive clinical benefit from this procedure. [14] [15] [16] [17] An effective salvage regimen remains to be defined for patients with advanced multiple myeloma being considered for RI-alloHSCT, as the overwhelming majority of myeloma patients who are currently referred for participation on RI-alloHSCT trials have already received most of the available novel agents. 18 As previously mentioned, full donor chimerism has been associated with disease outcome after RI-alloHSCT; however, host immune status, which affects engraftment, can be highly variable before transplant. We hypothesized that a salvage regimen that results in significant depletion of host lymphocytes, as well as provides disease control, would promote full donor chimerism after RI-alloHSCT and improve outcomes after transplant. The EPOCH regimen was originally developed on the hypothesis that continuous drug exposure may modulate the effects of the cell cycle and apoptosis on treatment response. 19 We modified the EPOCH regimen by adding fludarabine to purposely deplete host T cells to augment engraftment, as well as provide additional disease control, in patients with B-cell lymphomas undergoing RIalloHSCT. 20 As many of the agents contained within the resulting EPOCH-F regimen have shown efficacy against multiple myeloma, 21, 22 we tested this regimen for its safety, ability to deplete host lymphocytes and efficacy in patients with multiple myeloma being considered for RI-alloHSCT.
Patients and methods

Eligibility criteria
All patients were participants in the NCI (National Cancer Institute) protocols. The protocols were approved by the NCI Institutional Review Board and were registered as NCT00019851, NCT00020306, NCT00055744 and NCT00077480. Patient eligibility criteria for all protocols included the availability of HLA-matched sibling, age 18-75 years, ECOG (Eastern Cooperative Oncology Group) performance status of p1, life expectancy 43 months and adequate cardiac, pulmonary, renal and hepatic functions. Patients were excluded if they had infections not responding to antimicrobial therapy, active central nervous system involvement, a history of psychiatric disorder that did not permit them to give informed consent or were positive for HIV and hepatitis B or C. All protocols permitted patients to participate with disease that failed to respond to primary treatment, relapsed after autologous HSCT, or had less than a CR after salvage therapy. Protocol NCT00020306 permitted patients with responsive disease to first-line therapy to participate in the study.
As there were no previous safety data on combining fludarabine with EPOCH, patients received therapy in three cohorts on successive protocols, with each protocol permitting an escalation in the EPOCH-F regimen, as detailed below. All patients provided written, informed consent before participating in these trials. In the first cohort, no dose escalation was allowed, and the infusional chemotherapy and fludarabine was administered for only 3 days. In the second cohort, dose escalation of CY, etoposide and adriamycin was permitted on successive EPOCH-F cycles (as per description in Table 1 ). In the third cohort, dose escalation was permitted, and the regimen was extended from 3 days to the 4-day regimen defined above. Dose adjustments, based on the neutrophil nadir, were designed to adjust for interpatient variations in steady-state plasma concentrations (Table 2) . 19 All patients received filgrastim (5 mcg/kg/day) beginning on day 6 and continued until the ANC was 41000/mL on two occasions or 45000/mL once after the nadir. Cycles were repeated every 21 days, provided there was adequate hematological recovery (ANC 4500/mL and plt count 450 000/mL). Patients received prophylaxis with sulfamethoxazole and trimethoprim for Pneumocystis jiroveci pneumonia and with fluconazole for prophylaxis against yeast infections. Fluconazole was held on the days of chemotherapy because of potential interactions with VCR. Patients received up to five cycles of EPOCH-F, guided by their disease response and CD4
þ T-cell counts, which was used as a surrogate maker of host immune depletion. /day for 4 days (day À6 to day À3) or one additional cycle of EPOCH-F in the last cohort followed by transplantation. GVHD prophylaxis on these studies was provided with either cyclosporine alone or in combination with either sirolimus or MTX.
Study end points and statistical analysis
The primary end points of this analysis were response rates, toxicities and the degree of lymphocyte depletion with EPOCH-F before transplantation. The secondary end points were engraftment, response rates and survival after alloHSCT.
Response was evaluated using the EBMT (European Group for Blood and Marrow Transplantation) criteria available at the time these studies were performed. 23 Nearcomplete response (nCR) and very good partial response were defined as the absence of monoclonal protein by serum protein electrophoresis but detectable by immunofixation and X90% decrease in monoclonal protein and p5% plasma cells on BM examination, respectively. Chemotherapy sensitivity was defined as having at least a PR to therapy. Responses to EPOCH-F were assessed at the completion of EPOCH-F therapy, which was immediately before RI-alloHSCT. Responses after RI-alloHSCT were assessed at 28 and 100 days, and 6, 9 and 12 months after transplant, and every 6 months thereafter or if clinically indicated.
Data on demographics, response, immune depletion, chimerism, GVHD and toxicity (NCI Common Toxicity Criteria v2.0) were analyzed using descriptive statistics. Survival was determined using the Kaplan-Meier method, from the date of RI-alloHSCT until the date of death or last follow-up, whereas the probability of TRM was reported using a cumulative incidence plot, adjusting for the competing risk of death from disease. 24 Changes in absolute lymphocyte count and CD4 numbers were reported using the relative (percentage) change in the parameter compared with pretreatment, as this was less dependent on the baseline value than the absolute change. The significance of these changes from zero was determined using Wilcoxon's signed-rank test. All P-values were from two-tailed tests, with P-values of o0.05 considered to represent statistically significant differences.
Results
Patients and treatments
In all, 22 patients with multiple myeloma received treatment with EPOCH-F as a part of planned pretransplant therapy in the study. Baseline characteristics are shown in Table 3 . The median patient age was 53 years (range 36-65). The median number of previous therapies was three (range 1-8); 68% of patients had received a previous anthracycline, and 68% had received a previous novel agent (for example, thalidomide).
Toxicity of EPOCH-F
Patients received a median of three cycles (range 1-5) of EPOCH-F before RI-alloHSCT. All but one patient completed their planned treatment course with EPOCH-F. Overall, EPOCH-F was relatively well tolerated with clinically manageable grade III or IV hematologic toxicities (Table 4 ). The most common toxicity was grade IV neutropenia observed in 77% of the patients; the median duration of neutropenia was 4 days (range 2-10). This incidence and severity of neutropenia was expected, as the treatment was dose adjusted to achieve a nadir ANC o500/mL. In all, eight patients experienced grade III infection, Table 3 Baseline patient characteristics whereas only six patients experienced neutropenic fever, with no infection-related deaths. One patient died from an uncontrollable pericardial effusion and subsequent cardiovascular failure, which was not thought to be directly related to therapy, but to his underlying disease (plasma cell leukemia).
Immune-depleting effects of EPOCH-F EPOCH-F resulted in significant immune depletion. As shown in Table 5 , the median absolute lymphocyte count decreased from 1423/mL (range 335-2788) to 519/mL (range, 102-1420), with a corresponding median relative decrease of 64% per patient (P ¼ 0.0002), whereas CD4 counts decreased from a median of 320/mL (range 130-1366) to 115/mL (range 30-309), with a corresponding median relative decrease of 76% per patient (Po0.0001).
Response to EPOCH-F EPOCH-F showed an overall response (XPR) of 22%, whereas CR/nCR was observed in 13% of patients (Table 6 ). In addition, 68% (n ¼ 15) of patients had stable disease (SD). Only one patient progressed while on therapy. In the first cohort of patients (n ¼ 10), two achieved a PR, one had progressive disease and seven had stable disease. In the second cohort (n ¼ 8), in which dose escalation was allowed, there were six patients with stable disease and one with CR. In the last cohort (n ¼ 4) there were two CRs and two patients had stable disease.
Transplantation results
A total of 20 patients underwent RI-alloHSCT. Of the two patients who did not receive transplantation, one patient withdrew consent and the other, a patient with plasma cell leukemia, experienced a grade 4 toxicity (pericardial effusion) and was deemed ineligible to proceed to transplant. Thus, 19 patients were evaluable for engraftment; the median day 100 donor chimerism was 100% (range 60-100). The one patient who was not evaluable for day 100 chimerism died of a transplant-related complication (acute GVHD) at day 67 after transplant; however, his chimerism was 100% donor on his day 28 evaluation. There were no cases of primary or delayed graft failure. Acute GVHD grade II-IV was observed in 10 out of 19 (52%) patients. The overwhelming majority of acute GVHD cases were either grade II or III; one case of grade IV acute GVHD occurred in a patient who received cyclosporine alone as GVHD prophylaxis. Of the 18 evaluable patients, chronic GVHD was observed in 9 (50%) patients. Four patients died from progressive disease, whereas four died from infectious complications, one from acute GVHD and one from gastrointestinal hemorrhage related to transplant.
TRM at 100 days and 5 years was 5 and 30%, respectively. After RI-alloHSCT, 14 (70%) patients achieved very good partial response or better response, whereas CR/nCR was observed in 8 (40%) patients (Table 6 ). Eight (40%) of these best responses were observed at time points beyond their day 28 evaluation. Out of the 20 patients, 10 remain alive at the time of analysis with an estimated median potential follow-up of 44.6 months (range 1-69 þ months). The Kaplan-Meier estimate of median OS for all patients is 46.1 months (Figure 1 ).
Discussion
Myeloablative conditioning regimens are designed to produce tumor cytoreduction and provide immunosuppression sufficient to allow establishment of the donor graft. In contrast, non-myeloablative and RI conditioning regimens are designed more for immunosuppression than for cytoreduction, with the aim of establishing consistent donor engraftment while minimizing toxicity. Different RI conditioning regimens have been reported to result in varying degrees of donor engraftment with higher incidences of mixed chimerism when compared with myeloablative regimens.
12,15,25-27 EPOCH-F for MM before RI-alloHSCT S Jamshed et al Relapse, which is increased when compared with myeloablative conditioning regimens, is the primary cause of treatment failure after RI-alloHSCT. 28 As previously stated, relapse is highly associated with disease sensitivity to pre-transplant chemotherapy and post transplant donor chimerism. 29 Despite these observations, a preferred pretransplant chemotherapy regimen has not emerged for patients with multiple myeloma. To address the problems of engraftment and pre-transplant disease control, we tested the EPOCH-F regimen in myeloma patients being considered for RI-alloHSCT.
In our present study, EPOCH-F yielded a 22% overall response rate for previously treated myeloma patients; an additional 68% of patients maintained disease stability, with only one observed disease progression. The latter may be advantageous relative to time required to prepare for transplantation such as donor procurement. Although only four patients were treated in the final, third cohort that involved the extended 4-day period of infusional chemotherapy, it is perhaps significant to note that two of the four patients achieved a CR. As the 4-day regimen was also relatively well tolerated, we suggest that further clinical protocols in this area use the 4-day regimen of EPOCH-F. In a patient population of whom many had previously received anthracyclines, high-dose therapy and autologous HSCT, and novel agents, we were able to administer EPOCH-F with predictable and relatively manageable toxicities, with the primary toxicity of neutropenia being of relatively short duration and occurring during the second week of each cycle.
Importantly, EPOCH-F also resulted in significant lymphocyte depletion. The level of lymphocyte depletion achieved by the combination of EPOCH-F and the RI conditioning was similar to the level of immune suppression observed after myeloablative regimens but without the associated toxicities. This is supported by the observation of complete donor engraftment by day 28 in the overwhelming majority of patients (data not shown), which was sustained at day 100 without immune suppression withdrawal or donor lymphocyte infusion.
Our study showed that EPOCH-F is a relatively safe regimen that provides disease control and seems to augment engraftment by providing significant host lymphocyte depletion before transplant. Although the majority of patients who are referred have already received novel agents, the efficacy of EPOCH-F could be further enhanced by the incorporation of bortezomib or other agents, which we intend to investigate in combination with EPOCH-F in future trials. The potential incorporation of bortezomib is of particular interest relative to both its efficacy and immunomodulatory effects. 30, 31 The safety of such a regimen is likely acceptable, as EPOCH has already been successfully combined with bortezomib. 32 In summary, EPOCH-F is a novel pre-transplant regimen that provides both tumor control and lymphocyte depletion in multiple myeloma patients being considered for RI-alloHSCT.
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